The researchers also found that adding a protein called CD40L to B cells in the laboratory produced better and more efficient TIL expansion. Thus, the study suggests CD40L could be utilized in the ACT ...

For Biogen, dapirolizumab pegol is part of a push ... "Our hypothesis is that impacting the CD40L pathway, a central mechanism in immune response, would translate to significant impact on SLE ...